Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel

Last updated: September 12, 2023
Sponsor: Invitae Corporation
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pancreatic Cancer

Pancreatitis

Pancreatic Disorders

Treatment

No intervention

Clinical Study ID

NCT06043921
2021-003
  • Ages > 20
  • All Genders

Study Summary

This is a multicenter, prospective, observational study to evaluate the utility of the Invitae Personalized Cancer MonitoringTM assay for patients with resectable and unresectable pancreatic cancer. Using tumor tissue, a personalized blood test (the Invitae Personalized Cancer MonitoringTM test) will be developed that can be used for repeated monitoring to assess for the presence or absence of circulating tumor DNA (ctDNA). The presence of residual cancer cells after treatment is known as molecular residual disease (MRD) and the detection of ctDNA can provide evidence of the presence of MRD. Participants in this study will have their blood drawn at various time points throughout their cancer treatment to test for ctDNA and monitoring with the Invitae Personalized Cancer MonitoringTM test will continue until disease progression or the duration of the study.

Eligibility Criteria

Inclusion

Inclusion Criteria: A. Unresectable Pancreatic Cancer:

  1. At least 20 years of age at the time of consent
  2. Histopathologically confirmed adenocarcinoma and diagnosed as having ① or ② describedbelow within 60 days prior to enrollment
  • Clinical Stage Ⅲ (T1-3N2M0, T4 anyNM0)
  • Clinical Stage Ⅳ (anyTanyNM1)
  1. Scheduled to receive systemic chemotherapy for unresectable pancreatic cancer.
  2. No prior treatment for pancreatic cancer
  3. Willing to provide blood and tissue samples in accordance with the research protocol.
  4. Adequate tissue samples are available
  5. Written informed consent for participating in this study B. Resectable Pancreatic Cancer:
  6. At least 20 years of age at the time of consent.
  7. Tissue sample collected by EUS-FNA/FNB and histopathologically diagnosed as havingadenocarcinoma.
  8. Diagnosed as having cancer meet any one of a to d below within 60 days prior toenrollment
  9. cStage IA (T1 N0 M0)
  10. cStage IB (T2 N0 M0)
  11. cStage IIA (T3 N0 M0)
  12. cStage IIB (T1-3 N1 M0)
  13. Scheduled to undergo surgery for resectable pancreatic cancer.
  14. No history of prior treatment for pancreatic cancer.
  15. Willing to submit blood and tissue samples in accordance with the research protocol.
  16. Adequate tissue samples are available
  17. Written informed consent for participating in this study

Exclusion

Exclusion Criteria: Common exclusion criteria for both the unresectable and resectable pancreatic cancerpatient cohorts:

  1. Synchronous double/multiple cancer or metachronous double/multiple cancer withprogression free period of 2 years or shorter.
  2. Women who are pregnant or planning to become pregnant.
  3. Judged by the investigator as being unsuitable for participation in the study.

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: No intervention
Phase:
Study Start date:
November 01, 2022
Estimated Completion Date:
December 31, 2026

Study Description

This is a multi-site, prospective, observational trial in Japan of 150 pts with resectable (50) and unresectable (100) PC. The main eligibility criteria are histopathologically diagnosed as adenocarcinoma, no prior treatment for PC, scheduled to undergo surgery for resectable PC or receive systemic therapy for unresectable PC. In resectable PC cohort, blood samples will be collected before surgery and at 1, 3, 6, 9, 12, 18, and 24 months after surgery, and imaging study will be performed before surgery, and at 3, 6, 9, 12, 18, and 24 months after surgery. In the unresectable PC cohort, blood samples will be collected before treatment and at 4, 8, 12, 16, 24, 32, 40, and 48 weeks on treatment, and imaging study will be performed before treatment and every 8 weeks on treatment until 48 weeks. Primary endpoint in the resectable PC cohort is success rate of creating personalized panel using tumor tissue obtained by EUS-FNA/FNB, and that in unresectable PC cohort is rate of concordance of KRAS mutations between tumor tissue and blood samples. Key secondary endpoints in resectable PC cohort are rate of ctDNA positivity for each cancer stage before neoadjuvant chemotherapy and 4 weeks after surgery, and that in unresectable PC cohort is pretreatment ctDNA detection rate for each disease stage.

Connect with a study center

  • National Cancer Center Hospital East

    Kashiwa,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.